V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 210028128 | 210013827 | 0.81 | null | Curative (C) | 2017-03-05 | 2017-07-14 | BR14 TRIAL | null | null | 210030882 | OFATUMUMAB |
| 210028129 | 210013829 | 1.63 | 10.8 | Palliative (P) | 2016-10-10 | 2017-01-20 | PNET 4 HIT-SIOP Maintenance | 02 | N | 210030903 | CLL210 TRIAL |
| 210028130 | 210022634 | 1.7 | 103.4 | null | 2019-01-14 | 2019-02-13 | CARFILZOMIB | N | N | 210030950 | OBINUTUZUMAB |
| 210028131 | 210013832 | 1.7 | 14.9 | Disease modification (D) | 2016-04-06 | 2016-04-08 | CNS Medbl Std Risk Maint Cisplatin | 02 | N | 210031032 | CVP |
| 210028132 | 210013833 | 1.6 | 97.5 | Curative (C) | 2017-04-04 | 2017-04-11 | Lenalidomide Cycle 26 onwards (PAS) | N | N | 210031092 | CVD |
| 210028133 | 210013834 | null | 70.5 | null | 2016-08-08 | 2016-12-14 | BEAM | null | null | 210031093 | FLUOROURACIL |
| 210028134 | 210022638 | 0 | 46.3 | Disease modification (D) | 2018-07-18 | 2018-07-18 | Cytarabine intrathecal | N | null | 210031157 | CYTARABINE INTRATHECAL |
| 210028135 | 210013838 | 1.74 | 68 | Curative (C) | 2018-11-21 | 2018-11-28 | FLAG | N | null | 210031192 | CLOFARABINE + CYCLOPHOSPHAMIDE + ETOPOSIDE |
| 210028136 | 210013840 | null | 19.3 | null | 2016-10-13 | 2017-03-30 | Cytarabine intrathecal | N | N | 210031205 | OBINUTUZUMAB |
| 210028137 | 210013843 | 1.83 | 46 | null | 2017-05-26 | 2018-04-23 | Cyclophosphamide High Dose | Y | N | 210031222 | MYELOMA XI TRIAL |
| 210028138 | 210031578 | 1.73 | null | Adjuvant (A) | 2016-05-11 | 2016-05-11 | CARBO + ETOPOSIDE + VINCRISTINE | 02 | N | 210031222 | BEAM |
| 210028139 | 210036931 | 1.87 | 0 | Curative (C) | 2018-04-24 | 2018-04-28 | CLARITY Trial | N | N | 210031422 | IMMUNOGLOBULIN |
| 210028140 | 210022642 | 1.73 | 13.4 | Curative (C) | 2015-08-28 | 2015-08-31 | CYTARABINE + ETOPOSIDE + METHOTREXATE | N | N | 210031422 | CISPLATIN + ETOPOSIDE + IFOSFAMIDE |
| 210028141 | 210013846 | 1.7 | 62.9 | Adjuvant (A) | null | 2019-09-14 | CARBO + ETOPOSIDE + VINCRISTINE | N | N | 210031442 | CARFILZOMIB |
| 210028142 | 210013847 | 1.64 | 21.3 | Curative (C) | null | 2015-12-16 | Irinotecan + Temozolomide | N | N | 210031497 | BEAM |
| 210028143 | 210013848 | null | 79.5 | Adjuvant (A) | 2015-04-13 | 2015-04-18 | DA 3 + 10 | null | N | 210031558 | OXALIPLATIN + MDG |
| 210028144 | 210022645 | 1.82 | 83.4 | Palliative (P) | 2016-04-08 | 2018-03-25 | BEAM | N | N | 210031596 | IDARUBICIN + MERCAPTOPURINE + METHOTREXATE + VINCRISTINE |
| 210028145 | 210022645 | null | null | Adjuvant (A) | 2016-12-13 | 2016-12-13 | Cytarabine Intrathecal (any age) | 02 | N | 210031596 | MARALL TRIAL |
| 210028146 | 210013851 | 1.75 | 66.6 | Curative (C) | 2018-02-15 | 2018-03-07 | Bortezomib (weekly) | 02 | N | 210031639 | DOCETAXEL |
| 210028147 | 210013853 | null | 52.3 | Disease modification (D) | 2016-02-10 | 2016-02-10 | Docetaxel 75mg/m2 (21 day) | N | null | 210031768 | ALEMTUZUMAB + CYCLOPHOSPHAMIDE |
| 210028148 | 210013856 | 0 | 58.4 | Curative (C) | 2015-06-15 | 2015-06-17 | Docetaxel 75mg/m2 (21 day) | N | N | 210031789 | CYCLO + FLUDARABINE + RITUXIMAB |
| 210028149 | 210013857 | null | null | Curative (C) | 2018-04-11 | 2018-04-18 | Cytarabine intrathecal | null | N | 210031817 | DAUNORUBICIN + VNCRISTINE |
| 210028150 | 210013859 | 1.8 | 26 | Disease modification (D) | 2017-06-20 | 2017-10-15 | Cytarabine Intrathecal (any age) | N | N | 210031869 | CYTARABINE |
| 210028151 | 210013860 | 1.7 | 82.2 | Adjuvant (A) | 2017-12-11 | 2017-12-11 | PACLITAXEL | N | N | 210031901 | ALL |
| 210028152 | 210022651 | 1.8 | 64 | Curative (C) | 2017-03-24 | 2017-03-24 | FCR IV - Cycle 2 onwards | N | N | 210032089 | OFATUMUMAB |
| 210028153 | 210022652 | 1.74 | 74.6 | Disease modification (D) | 2017-03-13 | 2017-03-13 | Intensification 1 2 3(ALL) (Mtx) | null | N | 210032099 | TRASTUZUMAB |
| 210028154 | 210013863 | 0 | 52.3 | Disease modification (D) | null | 2018-02-23 | AML17 TRIAL | N | N | 210032185 | ALL MAINTENANCE |
| 210028155 | 210022653 | 1.61 | 59 | Palliative (P) | 2015-05-31 | 2015-06-01 | NHL 2003 Gp B COPADM 1 & 2 | 02 | N | 210032185 | PILOT TRIAL |
| 210028156 | 210013867 | 1.76 | 88.7 | Curative (C) | 2017-03-25 | 2017-03-29 | LENALIDOMIDE | 2 | Y | 210032363 | CYTARABINE HD + METHOTREXATE HD |
| 210028157 | 210013869 | null | 66.7 | Curative (C) | 2017-11-14 | 2018-11-02 | MERCAPTOPURINE + METHOTREXATE + VINCRISTINE | null | N | 210032409 | NILOTINIB |
| 210028158 | 210022655 | 1.77 | 50.1 | Curative (C) | 2017-01-15 | 2017-01-16 | Alemtuzumab + Cyclophos TBI Allo | N | N | 210032441 | UKALL2003 |
| 210028159 | 210022656 | 1.73 | 82.3 | Curative (C) | 2016-12-10 | 2019-01-27 | Nilotinib | null | N | 210032604 | RUXOLITINIB |
| 210028160 | 210013873 | null | 62.9 | Curative (C) | null | 2017-07-27 | FCR IV - Cycle 2 onwards | N | N | 210032637 | BEAM |
| 210028161 | 210013875 | 1.65 | 100 | Disease modification (D) | 2016-07-10 | 2016-07-16 | BEAM | Y | N | 210032710 | OFATUMUMAB |
| 210028162 | 210013876 | null | 70.4 | Curative (C) | 2018-09-24 | 2018-10-22 | Fludarabine oral | N | N | 210032730 | CAPECITABINE + OXALIPLATIN |
| 210028163 | 210013877 | null | 69 | Curative (C) | null | 2018-01-19 | PNET 4 HIT-SIOP Maintenance | 99 | null | 210032994 | ALEMTUZUMAB + ETOPOSIDE |
| 210028164 | 210013878 | 1.54 | 53 | Curative (C) | 2017-10-07 | 2017-10-12 | Irinotecan + Temozolomide | N | null | 210033021 | CYTARABINE HIGH DOSE |
| 210028165 | 210028217 | 1.66 | 39.1 | Palliative (P) | 2017-02-27 | 2017-02-27 | CISPLATIN + ETOPOSIDE | Y | N | 210033021 | CYCLO + FLUDARABINE + RITUXIMAB |
| 210028166 | 210013880 | 1.62 | 61.8 | Palliative (P) | 2017-01-17 | 2017-07-17 | ALL UKALL2003 C: Ph VII Maintenance | N | N | 210033199 | FLUDARABINE + RITUXIMAB |
| 210028167 | 210013880 | null | null | Curative (C) | 2015-09-06 | 2016-02-14 | TELOVAC TRIAL | Y | N | 210033199 | DAUNORUBICIN |
| 210028168 | 210013887 | 1.58 | 64.8 | Disease modification (D) | 2017-10-16 | 2017-10-26 | FCR IV - Cycle 2 onwards | N | N | 210033602 | CYCLOPHOSPHAMIDE + CYTARABINE |
| 210028169 | 210013890 | 1.73 | 83.7 | Curative (C) | 2019-07-27 | 2019-08-10 | CLARITY Trial | N | N | 210033677 | CYCLOPHOSPHAMIDE + ETOPOSIDE + NELARABINE |
| 210028170 | 210013895 | null | null | Palliative (P) | 2012-11-21 | 2013-08-13 | Cyclophos + Dex + Lenalidomide | 02 | N | 210033710 | NILOTINIB |
| 210028171 | 210013895 | 1.72 | 78 | Curative (C) | 2017-11-28 | 2017-11-28 | Cytarabine HD + Methotrexate HD | N | N | 210033710 | DHAP |
| 210028172 | 210013896 | 1.64 | 19.4 | Curative (C) | 2017-02-28 | 2017-06-02 | ICE-R (Cycle 1) | 2 | N | 210033781 | CYCLO + FLUDARABINE + RITUXIMAB |
| 210028173 | 210013898 | 0 | 65.3 | Palliative (P) | 2018-12-06 | 2018-12-19 | Nilotinib | N | N | 210033837 | HYDROXYCARBAMIDE |
| 210028174 | 210013902 | 1.81 | null | Not known (9) | 2018-02-28 | 2018-05-02 | BR14 TRIAL | 02 | N | 210033864 | HYDROXYCARBAMIDE |
| 210028175 | 210013905 | 1.75 | null | Curative (C) | 2017-05-20 | 2017-08-05 | DACTINOMYCIN + CYCLO + VINCRISTINE | 01 | N | 210033869 | CYCLO + FLUDARABINE + RITUXIMAB |
| 210028176 | 210013907 | 1.74 | 66.599 | Curative (C) | 2014-05-25 | 2014-05-30 | LEAM | 02 | N | 210034063 | DARATUMUMAB |
| 210028177 | 210022675 | null | null | Disease modification (D) | 2014-07-10 | 2014-07-10 | BR14 TRIAL | 02 | Y | 210034085 | CVP |